Widely used:Recently Viewed
Clear All
Value Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
₹1,16,531 Cr
26.04
4.11
36.7
0
16.63 %
22.77 %
0.9 %
351.18
58
₹25,971.01 Cr
₹36,263.61 Cr
₹20,119.58 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cipla
| -5.67 | -0.42 | -7.68 | 10.75 | 16.11 | 24.60 | 8.34 |
|
BSE Sensex
| -2.08 | -6.27 | -5.99 | 4.77 | 7.76 | 12.81 | 10.54 |
|
BSE Healthcare
| -5.55 | -3.36 | -4.46 | 31.00 | 18.30 | 25.19 | 11.10 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Cipla
| 15.83 | 13.97 | 14.21 | 72.29 | -8.57 | -15.04 | 6.98 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
--
--Min --Median --Max
--
--Min --Median --Max
--
Earnings Yield (%) = EBIT / Enterprise value
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,309.40 | 1,09,309.54 | 20.47 | 18.1 | |
| 2,600.40 | 1,07,308.65 | 50.74 | 21.23 | |
| 1,786.55 | 4,29,588.93 | 38.86 | 16.88 | |
| 3,174.85 | 1,07,610.42 | 59.72 | 24.24 |
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also... offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India. Read more
1935
Y K Hamied
Umang Vohra
Cipla
Mumbai, Maharashtra
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cipla Ltd stood at ₹ 34,655 Cr as on 30-Sep-24
The share price of Cipla Ltd is ₹1,442.30 (NSE) and ₹1,442.45 (BSE) as of 17-Jan-2025 15:57 IST. Cipla Ltd has given a return of 16.11% in the last 3 years.
Cipla Ltd has a market capitalisation of ₹ 1,16,531 Cr as on 17-Jan-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Cipla Ltd is 4.11 times as on 17-Jan-2025, a 30% discount to its peers’ median range of 5.86 times.
The P/E ratio of Cipla Ltd is 26.04 times as on 17-Jan-2025, a 29% discount to its peers’ median range of 36.70 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cipla Ltd and enter the required number of quantities and click on buy to purchase the shares of Cipla Ltd.
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
The prominent promoters of Cipla Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Yusuf Khwaja Hameid |
18.68%
|
|
SOPHIE AHMED |
5.71%
|
|
M K HAMIED |
3.46%
|
The chairman of the company is Y K Hamied, and the managing director is Umang Vohra.
There is no promoter pledging in Cipla Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,28,533
|
|
|
1,12,998
|
|
|
1,12,971
|
|
|
1,10,870
|
| Cipla Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
16.76
|
|
Operating margin(%)
|
21.22
|
|
Net Margin(%)
|
16.43
|
|
Dividend yield(%)
|
0.9
|
Yes, TTM profit after tax of Cipla Ltd was ₹4,475 Cr.
₹-1.20
(
